Replimune adds a $55M round and some expert help as it pursues next-gen oncolytics R&D
Some of the pioneers in oncolytics drug development have gone back to the venture well to finance their latest play in the field. Replimune, which …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
